Cited by 115Nanoparticle-Based Drug DeliveryDrug Transport and Resistance MechanismsRNA Interference and Gene Delivery

The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.

Combination therapy based on nano codelivery for overcoming cancer drug resistance

Open access

Wang, Hairui, Huang, Yongzhuo·2020·Medicine in Drug Discovery

DOI 10.1016/j.medidd.2020.100024

Open this paper in CoChat — free account Open PDF

Abstract

Multidrug resistance (MDR) has long been a major obstacle in the treatment of malignant tumors. Combination therapy provides a viable and promising strategy to overcome MDR. This article discusses the advantages of nano-based combination therapy and proposes a 3R delivery principle (right place, right time, and right dose) as a reference for development of cancer nanomedicine containing drug combinations. The article also reviews the strategies of nano-based codelivery, with emphasis on the techniques designed to overcome chemoresistance, enhance drug targeting delivery, and reduce immunosuppression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.medidd.2020.100024

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance
Wang, H., Gao, Z. J., Liu, X., Agarwal, P., Zhao, S., Conroy, D. W., Ji, G., Yu, J., Jaroniec, C. P., Liu, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02915-8 · Cited by 331
Self-citation
Retracted
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Metabolic reprogramming in macrophages and dendritic cells in innate immunity
Kelly, B., & O'Neill, L. A. (2015) · Cell Research · doi:10.1038/cr.2015.68 · Cited by 1,876
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,739
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Feng, R., Zong, Y., Cao, S., & Xu, R. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0368-6 · Cited by 1,646
Targeting metastasis
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z., Li, Y. X., & Chen, Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 996
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D. H., Collins, L. I., Piwnica-Worms, D. R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 964
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 733
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 688
Autophagy and multidrug resistance in cancer
Li, Y., Lei, Y., Yao, N., Wang, C., Hu, N., Ye, W., Zhang, D., & Chen, Z. (2017) · 癌症：英文版 · doi:10.1186/s40880-017-0219-2 · Cited by 678
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 641
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 575
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review
Riaz, M. K., Riaz, M., Zhang, X., Lin, C., Wong, K. H., Chen, X., Zhang, G., Lü, A., & Yang, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010195 · Cited by 510
Tumor microenvironment and cancer therapy resistance
Sun, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 391
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Nanoparticles for combination drug therapy
Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
Tardi, P. G., Johnstone, S. A., Harasym, N. L., Xie, S., Harasym, T. O., Zisman, N., Harvie, P., Bermudes, D. G., & Mayer, L. D. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 357
Molecular mechanisms of drug resistance and its reversal in cancer
Yandım, M. K., Adan, A., & Baran, Y. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1015957 · Cited by 350
From mice to humans: developments in cancer immunoediting
Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 324
The role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 313
Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes
Hansen, A. E., Petersen, A. L., Henriksen, J. R., Børresen, B., Rasmussen, P., Elema, D. R., af Rosenschöld, P. M., Kristensen, A. T., Kjær, A., & Andresen, T. L. (2015) · ACS Nano · doi:10.1021/acsnano.5b01324 · Cited by 277
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases
Chen, Z., & Tiwari, A. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08235.x · Cited by 274
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 264
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 263
Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications
Wu, W., Luo, L., Wang, Y., Wu, Q., Dai, H.-B., Li, J., Durkan, C., Wang, N., & Wang, G. (2018) · Theranostics · doi:10.7150/thno.23459 · Cited by 255
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Suda, K., Onozato, R., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913c9f · Cited by 233
Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery
Jin, H., He, Y., Zhao, P., Hu, Y., Tao, J., Chen, J., & Huang, Y. (2018) · Theranostics · doi:10.7150/thno.27246 · Cited by 221
Self-citation
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Mechanisms of Multidrug Resistance in Cancer Treatment
Harris, A. L., & Hochhauser, D. (1992) · Acta Oncologica · doi:10.3109/02841869209088904 · Cited by 208
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1
Wang, H., Tang, Y., Fang, Y., Zhang, M., Wang, H., He, Z., Wang, B., Xu, Q., & Huang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00021 · Cited by 195
Self-citation
Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment
Bosc, C., Selak, M. A., & Sarry, J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.013 · Cited by 193
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
Christie, E. L., Pattnaik, S., Beach, J. A., Copeland, A., Rashoo, N., Fereday, S., Hendley, J., Alsop, K., Brady, S. W., Lamb, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09312-9 · Cited by 193
The roles of glucose metabolic reprogramming in chemo- and radio-resistance
Lin, J., Xia, L., Liang, J., Han, Y., Wang, H., Oyang, L., Tan, S., Tian, Y., Rao, S., Chen, X., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1214-z · Cited by 193
Self-citation
Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
Sabnis, A. J., & Bivona, T. G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.009 · Cited by 187
Mechanisms of acquired tumor drug resistance
Алексахина, С. Н., Kashyap, A., & Имянитов, Е. Н. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188310 · Cited by 181
Mitochondria-Targeting Polydopamine Nanoparticles To Deliver Doxorubicin for Overcoming Drug Resistance
Li, W.-Q., Wang, Z., Hao, S., He, H., Wan, Y., Zhu, C., Sun, L.-P., Cheng, G., & Zheng, S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01540 · Cited by 173
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 172
Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response
Mellor, H. R., & Callaghan, R. (2008) · Pharmacology · doi:10.1159/000115967 · Cited by 170
Dual‐Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug‐Resistant Cancer Therapy
Zhao, P., Yin, W., Wu, A., Tang, Y., Wang, J., Pan, Z., Lin, T., Zhang, M., Chen, B., Duan, Y., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201700403 · Cited by 160
Self-citation
The beginning of the end of the nanomedicine hype
Park, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.044 · Cited by 158
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156
Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis
Ojha, R., Bhattacharyya, S., & Singh, S. K. (2015) · BioResearch open access · doi:10.1089/biores.2014.0035 · Cited by 152
Designer combination therapy for cancer
Lane, D. P. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-163 · Cited by 145
The therapeutic potential of targeting ABC transporters to combat multi-drug resistance
Bugde, P., Biswas, R., Mérien, F., Lu, J., Liu, D., Chen, M., Zhou, S., & Li, Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1310841 · Cited by 141
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Zhang, M., Liu, E., Cui, Y., & Huang, Y. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0054 · Cited by 134
Self-citation
Drug delivery micelles with efficient near-infrared photosensitizer for combined image-guided photodynamic therapy and chemotherapy of drug-resistant cancer
Zhen, S., Yi, X., Zhao, Z., Lou, X., Xia, F., & Tang, B. Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119330 · Cited by 134
Stimuli sensitive polymers and self regulated drug delivery systems: A very partial review
Siegel, R. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.035 · Cited by 128
Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties
Li, R., & Xie, Y. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.020 · Cited by 128
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance
Chen, S., Yang, K., Tuguntaev, R. G., Mozhi, A., Zhang, J., Wang, P. C., & Liang, X. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.10.020 · Cited by 127
Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning
Milane, L. S., Duan, Z., & Amiji, M. M. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-3 · Cited by 120
Autophagy and Hallmarks of Cancer
Huang, T., Song, X., Yang, Y., Wan, X., Alvarez, A. A., Sastry, N. G., Feng, H., Hu, B., & Cheng, S. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018027913 · Cited by 120
Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy
Kang, X., Wang, H., Peng, H., Chen, B., Zhang, W., Wu, A., Xu, Q., & Huang, Y. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.10 · Cited by 117
Self-citation
Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat
Peng, H., Chen, B., Huang, W., Tang, Y., Jiang, Y., Zhang, W., & Huang, Y. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03756 · Cited by 114
Self-citation
pH/Redox Dual-Responsive Polyplex with Effective Endosomal Escape for Codelivery of siRNA and Doxorubicin against Drug-Resistant Cancer Cells
Gao, Y., Li, J., Wang, Q., Hu, H., Zhao, X., Chen, D., & Qiao, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b02016 · Cited by 110
Role of the tumor microenvironment in the pathogenesis of gastric carcinoma
Chung, H. W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1667 · Cited by 106
MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer
Lu, X. J., Liu, R., Wang, M., Kumar, A. K., Pan, F., He, L., Hu, Z., & Guo, Z. (2019) · Oncogene · doi:10.1038/s41388-019-0986-0 · Cited by 105
Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis
Tang, Y., Liang, J., Wu, A., Chen, Y., Zhao, P., Lin, T., Zhang, M., Xu, Q., Wang, J., & Huang, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b05292 · Cited by 104
Self-citation
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
Qie, S., Yoshida, A., Parnham, S. R., Oleinik, N. V., Beeson, G. C., Beeson, C. C., Öğretmen, B., Bass, A. J., Wong, K., Rustgi, A. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09179-w · Cited by 101
Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles
Wu, Y., Zhang, Y., Zhang, W., Sun, C., Wu, J., & Tang, J. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.11.041 · Cited by 100
Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting
Zhou, M., Li, L., Li, L., Lin, X., Wang, F., Li, Q., & Huang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.005 · Cited by 99
Self-citation
Eugenol potentiates cisplatin anti‐cancer activity through inhibition of ALDH‐positive breast cancer stem cells and the NF‐κB signaling pathway
Islam, S. S., Al-Sharif, I. S., Sultan, A. M., Al‐Mazrou, A., Remmal, A., & Aboussekhra, A. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22758 · Cited by 90
Temporally Controlled Photothermal/Photodynamic and Combined Therapy for Overcoming Multidrug Resistance of Cancer by Polydopamine Nanoclustered Micelles
Xing, Y., Ding, T., Wang, Z., Wang, L., Guan, H., Tang, J., Mo, D., & Zhang, J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b00472 · Cited by 90
A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer
Chen, M., Song, F., Liu, Y., Tian, J. H., Liu, C., Li, R., & Zhang, Q. (2018) · Nanoscale · doi:10.1039/c8nr06218h · Cited by 86
Atg2A/B deficiency switches cytoprotective autophagy to non-canonical caspase-8 activation and apoptosis
Tang, Z., Takahashi, Y., Chen, C., Liu, Y., He, H., Tsotakos, N., Serfass, J. M., Gebru, M. T., Chen, H., Young, M. M., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.133 · Cited by 84
Self-citation
Enhancing tumor chemotherapy and overcoming drug resistance through autophagy-mediated intracellular dissolution of zinc oxide nanoparticles
Hu, Y. B., Zhang, H., Dong, L., Xu, M., Zhang, L., Ding, W., Zhang, J., Lin, J., Zhang, Y., Qiu, B., et al. (2019) · Nanoscale · doi:10.1039/c8nr08442d · Cited by 83
Tumor-homing, pH- and ultrasound-responsive polypeptide-doxorubicin nanoconjugates overcome doxorubicin resistance in cancer therapy
Wang, Z., He, Q., Zhao, W., Luo, J., & Gao, W. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.017 · Cited by 80
Remodeling Tumor‐Associated Macrophages and Neovascularization Overcomes EGFRT790M‐Associated Drug Resistance by PD‐L1 Nanobody‐Mediated Codelivery
Yin, W., Yu, X., Kang, X., Zhao, Y., Zhao, P., Jin, H., Fu, X., Wan, Y., Peng, C., & Huang, Y. (2018) · Small · doi:10.1002/smll.201802372 · Cited by 80
Self-citation
Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles
Valencia, P. M., Pridgen, E. M., Perea, B., Gadde, S., Sweeney, C. J., Kantoff, P. W., Bander, N. H., Lippard, S. J., Langer, R., Karnik, R., et al. (2012) · Nanomedicine · doi:10.2217/nnm.12.134 · Cited by 75
Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer
Shee, K., Yang, W., Hinds, J. W., Hampsch, R. A., Varn, F. S., Traphagen, N. A., Patel, K., Cheng, C., Jenkins, N. P., Kettenbach, A. N., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171818 · Cited by 75
Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites
Xu, F., Zhong, H., Chang, Y., Li, D., Jin, H., Zhang, M., Wang, H., Jiang, C., Shen, Y., & Huang, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.12.018 · Cited by 74
Self-citation
Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
Cho, J., Chang, Y. H., Heo, Y. J., Kim, S., Kim, N. K. D., Park, J. O., Kang, W. K., Lee, J., & Kim, K. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000326 · Cited by 74
Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma
Fianco, G., Mongiardi, M. P., Levi, A., Luca, T. D., Desideri, M., Trisciuoglio, D., Bufalo, D. D., Cinà, I., Benedetto, A. D., Mottolese, M., et al. (2017) · eLife · doi:10.7554/elife.22593 · Cited by 73
Paraptosis‐Inducing Nanomedicine Overcomes Cancer Drug Resistance for a Potent Cancer Therapy
Zhou, Y., Huang, F., Yang, Y., Wang, P., Zhang, Z., Tang, Y., Shen, Y., & Wang, K. (2018) · Small · doi:10.1002/smll.201702446 · Cited by 71
Mitochondrial Surface Engineering for Multidrug Resistance Reversal
Chen, W., Shi, K., Chu, B., Wei, X., & Qian, Z. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b05188 · Cited by 68
Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in Glioblastoma
Fianco, G., Contadini, C., Ferri, A., Cirotti, C., Stagni, V., & Barilà, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123798 · Cited by 62
Enhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug delivery
Zhang, L., Su, H., Liu, Y., Pang, N., Li, J., & Qi, X. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.004 · Cited by 60
Programmable Codelivery of Doxorubicin and Apatinib Using an Implantable Hierarchical‐Structured Fiber Device for Overcoming Cancer Multidrug Resistance
He, Y., Li, X., Ma, J., Ni, G., Yang, G., & Zhou, S. (2019) · Small · doi:10.1002/smll.201804397 · Cited by 59
Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance
Fang, L., Qin, X., Zhao, J., & Gou, S. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b03386 · Cited by 55
Acquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 51
Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy
Wang, S., Xu, Y., Chan, H. F., Kim, H., Wang, Y., Leong, K. W., & Chen, M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.018 · Cited by 50
Dual‐Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug‐Resistant Cancer Therapy
Zhao, P., Yin, W., Wu, A., Tang, Y., Wang, J., Pan, Z., Lin, T., Zhang, M., Chen, B., Duan, Y., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910144 · Cited by 50
Self-citation
pH- and photothermal-driven multistage delivery nanoplatform for overcoming cancer drug resistance
Huang, W., Zhao, H., Wan, J., Zhou, Y., Xu, Q., Zhao, Y., Yang, X., & Gan, L. (2019) · Theranostics · doi:10.7150/thno.33958 · Cited by 47
Combination of drugs and carriers in drug delivery technology and its development
Du, Y., & Chen, B. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s198056 · Cited by 45
Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment
Li, Y., Luo, J., Lin, M., Zhi, P., Guo, W.-W., Han, M. Y., You, J., & Gao, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00199 · Cited by 45
EPR or no EPR? The billion-dollar question
Wang, A. Z. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8108 · Cited by 44
Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Waterhouse, D., Gelmon, K. A., Klasa, R. J., Chi, K., Huntsman, D. D., Ramsay, E., Wasan, E. K., Edwards, L., Tucker, C., Zastre, J. A., et al. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906778194586 · Cited by 42
Chemotherapy and immunotherapy combination in advanced prostate cancer.
Slovin, S. F. (2012) · PubMed · Cited by 39
Cancer Targeting: Responsive Polymers for Stimuli-Sensitive Drug Delivery
Bhatnagar, S., & Venuganti, V. V. K. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2015.10325 · Cited by 36
SHR ‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD 9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
Tong, M., Gao, M., Xu, Y., Li, F., Li, Y., Bao, X., Fu, H., Quan, H., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.14180 · Cited by 27
Role of tumor hypoxia in acquisition of resistance to microtubule-stabilizing drugs
Das, V., Štěpánková, J., Hajdúch, M., & Miller, J. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.02.001 · Cited by 26
Folate-Targeted Redox-Responsive Polymersomes Loaded with Chemotherapeutic Drugs and Tariquidar to Overcome Drug Resistance
Qin, Y., Zhang, Z., Huang, C., Fan, F., Liu, L., Li, L., Wang, H., Liu, Z., Yang, J., Wang, C., et al. (2018) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2018.2623 · Cited by 26
Self-citation
Nanoparticle–Peptide–Drug Bioconjugates for Unassisted Defeat of Multidrug Resistance in a Model Cancer Cell Line
Sangtani, A., Petryayeva, E., Susumu, K., Oh, E., Huston, A. L., Lasarte‐Aragonés, G., Medintz, I. L., Algar, W. R., & Delehanty, J. B. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00755 · Cited by 24
Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
Xu, W., Tang, W., Li, T., Zhang, X., & Sun, Y. (2019) · Neoplasia · doi:10.1016/j.neo.2018.11.004 · Cited by 23
Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy
Zhang, R., Wang, S., Chen, A., Chen, W., Liu, Y., Wu, W., Kang, Y., & Ye, S.-F. (2015) · Journal of Biomaterials Applications · doi:10.1177/0885328215579297 · Cited by 19
Molecular mechanisms of drug resistance
Mader, R. M., Schmidt, W. M., Steger, G. G., & Krupitza, G. (2009) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp47049 · Cited by 15
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Bahri, M., Fleurence, J., Faraj, S., Daho, M. B. M., Fougeray, S., & Birklé, S. (2019) · Journal of Visualized Experiments · doi:10.3791/58291 · Cited by 5
Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice
Luhn, T., Chui, S., Hsieh, A., Yi, J.-H., Mecke, A., Bajaj, P., Hasnain, W., Falgas, A., Ton, T. G. N., & Kurian, A. W. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy272.306 · Cited by 2

Flagged first, then by citations

Research works printed but not linked: 1

Sharma, 2017, Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy, Cell, 168, 707

Sorted by citations

Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Advances in drug delivery systems, challenges and future directions
Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17488 · Cited by 1,040
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
Lactate and lactylation in cancer
Chen, J., Huang, Z., Chen, Y., Tian, H., Chai, P., Shen, Y., Yao, Y., Xu, S., Ge, S., & Jia, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02082-x · Cited by 545
Liposomes for Tumor Targeted Therapy: A Review
Wang, S., Chen, Y., Guo, J., & Huang, Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032643 · Cited by 340

See all 115

Authors: Wang, H., & Huang, Y.
Affiliations: Chinese Academy of Sciences (CN)
Corresponding author: Huang, Yongzhuo
ORCID: Wang, Hairui
Huang, Yongzhuo
Venue: Medicine in Drug Discovery
Publisher: Elsevier BV
Published: 2020-06
Volume: 6
Pages: 100024
ISSN: 2590-0986 (ISSN-L)
DOI: 10.1016/j.medidd.2020.100024
OpenAlex: W3014110015
Cited by: 115
References: 112
Citations by year: 2026: 6 · 2025: 23 · 2024: 23 · 2023: 24 · 2022: 24 · 2021: 13 · 2020: 2
FWCI: 4.10
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Medicine in Drug Discovery (publishedVersion, cc-by-nc-nd)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Natural Science Foundation of China
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: multidrug resistance, combination therapy, cancer nanomedicine, chemoresistance, immunosuppression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combination therapy based on nano codelivery for overcoming cancer drug resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks